Clearmind Medicine Reports Positive Retention Results for Intranasal MEAI

Key Highlights

• Clearmind Medicine reported positive ex vivo mucoadhesion results for its intranasal MEAI formulation.
• The formulation demonstrated markedly improved nasal residence characteristics compared to a standard MEAI solution.
• The study evaluated the ability of the formulation to remain associated with rabbit nasal tissue over a 30-minute period.
• Intranasal MEAI consistently maintained a greater proportion of its initially adhered dose throughout the evaluation.
• Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential.
• Results reinforce Clearmind's strategy for developing treatments for Alcohol Use Disorder (AUD) and other indications.
• The study provides further validation of Clearmind’s nasal drug-delivery platform.